Zyprexa is bringing in a significant amount of money for Lilly currently, and though patent protection will expire by 2011, there are a few promising drugs in the "product pipeline" that may enter the market in the near future.
A stronger dollar helped Eli Lilly & Co. (LLY) report higher-than-expected quarterly profit on Monday. The company reported it was able to control costs and revalue overseas inventory as the strong dollar contributed to increased profitability. Earnings increased to $1.31 billion, or $1.20 per share, from $1.06 billion, or 97 cents per share, in the year-earlier period. The results far exceeded Wall Street forecasts, Reuters reported.